FR2229412A1 - - Google Patents
Info
- Publication number
- FR2229412A1 FR2229412A1 FR7417124A FR7417124A FR2229412A1 FR 2229412 A1 FR2229412 A1 FR 2229412A1 FR 7417124 A FR7417124 A FR 7417124A FR 7417124 A FR7417124 A FR 7417124A FR 2229412 A1 FR2229412 A1 FR 2229412A1
- Authority
- FR
- France
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE7306960A SE7306960L (https=) | 1973-05-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FR2229412A1 true FR2229412A1 (https=) | 1974-12-13 |
Family
ID=20317502
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR7417124A Withdrawn FR2229412A1 (https=) | 1973-05-17 | 1974-05-16 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US3961060A (https=) |
| JP (1) | JPS5029716A (https=) |
| AU (1) | AU6889274A (https=) |
| DE (1) | DE2423529A1 (https=) |
| FI (1) | FI152074A7 (https=) |
| FR (1) | FR2229412A1 (https=) |
| NL (1) | NL7406689A (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0228253A1 (en) * | 1985-12-30 | 1987-07-08 | Merck & Co. Inc. | Rectally absorbable form of L-dopa |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2856393C2 (de) * | 1978-12-27 | 1983-04-28 | Merz + Co GmbH & Co, 6000 Frankfurt | Arzneimittel zur Behandlung von Morbus Parkinson |
| JPS5852219A (ja) * | 1981-09-22 | 1983-03-28 | Sumitomo Chem Co Ltd | パ−キンソン病治療剤 |
| US4843071A (en) * | 1986-12-05 | 1989-06-27 | Serotonin Industries Of Charleston | Method and composition for treating obesity, drug abuse, and narcolepsy |
| US5753712A (en) * | 1994-02-18 | 1998-05-19 | Pinsker; Walter | Treatment of migraine headaches and formulations |
| US5786360A (en) * | 1996-11-19 | 1998-07-28 | Link Technology Incorporated | A1 adenosine receptor antagonists |
| US5945424A (en) * | 1998-07-31 | 1999-08-31 | G & H Associates, Inc. | Treatment of periodic limb movement syndrome |
| WO2001032170A1 (en) | 1999-09-13 | 2001-05-10 | Swope David M | Composition and method for decreasing neurologic symptomatology |
| AU2001261022A1 (en) * | 2000-05-24 | 2001-12-03 | Eli Lilly And Company | Combination therapy for treatment of depression comprising an antidepressant and an ampa receptor potentiator |
| IT1317049B1 (it) * | 2000-06-23 | 2003-05-26 | Sigma Tau Ind Farmaceuti | Composti utili per la preparazione di medicamenti ad attivita'inibitrice della fosfodiesterasi iv. |
| US20030092770A1 (en) * | 2002-10-23 | 2003-05-15 | Phil Skolnick | Combination therapy for treatment of depression |
| US8338420B1 (en) | 2002-12-04 | 2012-12-25 | Mitsubishi Tanabe Pharma Corporation | Treatment of Parkinson's disease and enhancement of dopamine signal using PDE 10 inhibitor |
| JP2006518390A (ja) * | 2003-02-19 | 2006-08-10 | エンダシア，インコーポレイテッド | Ａ１アデノシンレセプターアンタゴニスト |
| US7943632B2 (en) * | 2003-03-17 | 2011-05-17 | Neurohealing Pharmaceuticals, Inc. | High potency dopaminergic treatment of neurological impairment associated with brain injury |
| CA2519117C (en) * | 2003-03-17 | 2010-03-02 | Neurohealing Pharmaceuticals, Inc. | High potency dopaminergic treatment of neurological impairment associated with brain injury |
| CA2528385C (en) * | 2003-06-06 | 2011-03-15 | Endacea, Inc. | A1 adenosine receptor antogonists |
| WO2004110379A2 (en) * | 2003-06-09 | 2004-12-23 | Endacea, Inc. | A1 adenosine receptor antagonists |
| US8440685B1 (en) | 2004-09-20 | 2013-05-14 | MedDEV, Inc. | Method for treatment of neurologic dysfunction |
| US9364474B2 (en) | 2004-09-20 | 2016-06-14 | Meddev Inc. | Method for treatment of neurologic dysfunction |
| US7645766B1 (en) * | 2004-09-20 | 2010-01-12 | MedDEV, Inc. | Method for treatment of depression and depressive mood disorders |
| WO2010134074A1 (en) * | 2009-05-19 | 2010-11-25 | Neuroderm Ltd | Compositions for continuous administration of dopa decarboxylase inhibitors |
| WO2013016662A1 (en) * | 2011-07-28 | 2013-01-31 | Memorial Sloan-Kettering Cancer Center | Diagnosis and treatment of parkinson's disease |
| WO2014138708A1 (en) | 2013-03-08 | 2014-09-12 | Yu Benjamin M | Methods and compositions for transdermal delivery of caffeine in the forms of solution or suspension |
| CA2940454A1 (en) | 2014-03-10 | 2015-09-17 | Benjamin M. YU | Methods and compositions for transdermal delivery |
| US10258585B2 (en) | 2014-03-13 | 2019-04-16 | Neuroderm, Ltd. | DOPA decarboxylase inhibitor compositions |
| ES2967693T3 (es) | 2014-03-13 | 2024-05-03 | Neuroderm Ltd | Composiciones del inhibidor de la dopa descarboxilasa |
| US11213502B1 (en) | 2020-11-17 | 2022-01-04 | Neuroderm, Ltd. | Method for treatment of parkinson's disease |
| US11331293B1 (en) | 2020-11-17 | 2022-05-17 | Neuroderm, Ltd. | Method for treatment of Parkinson's disease |
| US11844754B2 (en) | 2020-11-17 | 2023-12-19 | Neuroderm, Ltd. | Methods for treatment of Parkinson's disease |
| US12161612B2 (en) | 2023-04-14 | 2024-12-10 | Neuroderm, Ltd. | Methods and compositions for reducing symptoms of Parkinson's disease |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3646213A (en) * | 1970-08-12 | 1972-02-29 | Hoffmann La Roche | Compositions and methods for treating depression with combinations of l-3 4-dihydroxyphenylalanine and a hydrazine |
-
1974
- 1974-05-14 AU AU68892/74A patent/AU6889274A/en not_active Expired
- 1974-05-15 DE DE2423529A patent/DE2423529A1/de active Pending
- 1974-05-15 US US05/469,954 patent/US3961060A/en not_active Expired - Lifetime
- 1974-05-16 FR FR7417124A patent/FR2229412A1/fr not_active Withdrawn
- 1974-05-16 FI FI1520/74A patent/FI152074A7/fi unknown
- 1974-05-16 JP JP49053962A patent/JPS5029716A/ja active Pending
- 1974-05-17 NL NL7406689A patent/NL7406689A/xx unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0228253A1 (en) * | 1985-12-30 | 1987-07-08 | Merck & Co. Inc. | Rectally absorbable form of L-dopa |
Also Published As
| Publication number | Publication date |
|---|---|
| DE2423529A1 (de) | 1974-12-05 |
| US3961060A (en) | 1976-06-01 |
| FI152074A7 (https=) | 1974-11-18 |
| JPS5029716A (https=) | 1975-03-25 |
| NL7406689A (https=) | 1974-11-19 |
| AU6889274A (en) | 1975-11-20 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RE | Withdrawal of published application |